News

News - 2018


October 2018

Quality Control in the Production of Radiopharmaceuticals

Advances have led to the production of new radiopharmaceuticals and availability of new production routes. Various new diagnostic agents in the field (such as Ga-68 radiopharmaceuticals and generators) as well as therapeutic agents (such as alpha emitters) have been added to the clinician’s menu. It is essential that radiopharmaceuticals are prepared within a robust quality control system encompassing materials and personnel, with adequate documentation, and continuous review of ongoing results. This publication provides guidelines and best practices for the quality control of medical radioisotopes and radiopharmaceuticals. It was written by a group of experts with experience across a range of radiopharmaceuticals and is intended to support professionals in the preparation of good quality and safe products to be used in nuclear medicine procedures.

Click here for more information.


June 2018

Darlington to supply moly-99

Ontario Power Generation's (OPG) Darlington nuclear power plant is to produce molybdenum-99 (Mo-99) for use in new technetium-99m (Tc-99m) generators designed by BWX Technologies Inc. The Candu plant will be the first large-scale commercial nuclear power plant in the world to produce Mo-99.

http://www.world-nuclear-news.org/RS-Darlington-to-supply-molybdenum-99-2106187.html


April 2018

Mo-99 Production Activities at NTP Radioisotopes (NTP) and I-131 Supply Situation

NTP reported that it received approval from the South African Nuclear Regulator to return to normal operations through the end of June 2018. During this period, NTP will engage with the NNR to ensure continued normal operation from July 2018 onwards. NTP also stated that as a result of this approval, NTP will be in a position to manufacture I-131 to assist with the international shortage.


March 2018

Emeritus Winner

Dr. John Powe - Vancouver

2018 Eric Lepp Recipient 

Dr. Caroline Malo Pion, Montréal


Past News - 2017


July 2017

Beta, BTG’s Education, Training and Audit program

Beta, BTG’s Education, Training and Audit program is designed to reduce the risk of radiation exposure when performing selective internal radiation therapy (SIRT) by increasing awareness of radiation safety and providing risk education.

For more information, click here:


IAEA Webinars and E-Learning Modules

Free IAEA Webinars and e-learning modules available

For more information, click here:


May 2017


Hermes - News Letter and Press Release

The Board of Directors for Hermes Medical Solutions AB has appointed Mikael Strindlund as new President and CEO. Hermes Medical Solutions is a global leader in digital medical imaging with a focus on end-to-end clinical IT-solutions within molecular imaging and radiology. 

Click here to view Newsletter

Click here  to view Press Release.

********************

Le Patient March-April 2017

To view all Le Patient editions, click here.


Past News - 2016


November 2016


Canada 2020-A New Health Accord for all Canadians - November 2016

Conference Report - The presentations and debates heard at Canada 2020’s Health Summit included many recommendations about how Canada’s health system can be improved.
Click here to view report


 ************************

October 2016

Lantheus Medical Imaging, Inc. is committed to ensuring that the medical imaging community has reliable and secure access to TechneLite® (Technetium Tc 99m Generator) to meet the healthcare needs of patients. We believe we have the most globally balanced and diversified supply of molybdendum-99 (Mo-99), the parent isotope of technetium-99m, in the industry which provides us with reliable access and capacity to meet our customers’ needs.

To read more, click here

************************

September 2016

Lantheus letter on Mo99 supply - September 28, 2016


Lantheus Medical Imaging, Inc. is committed to ensuring that the medical imaging community has reliable and secure access to TechneLite® (Technetium Tc 99m Generator) to meet the healthcare needs of patients. We believe we have the most globally balanced and diversified supply of molybdendum-99 (Mo-99), the parent isotope of technetium-99m, in the industry which provides us with reliable access and capacity to meet our customers’ needs.


Read full letter by clicking here.


*******************

July 2016

GE Healthcare regrets to inform you that the expected return DMSA (Kit for the Preparation of Technetium Tc99m Succimer Injection) to the global market has been delayed indefinitely.  We will be unable to provide supply of DMSA to our customers until further notice.

To read more, click here.

************************


WFNMB-Presidency Bid Presidency Candidate:  Dr. Jean-Luc Urbain
Read More

************************

Comments to USP Chapter 797-Compounding Radiopharmaceuticals-SNMMI
Read More

New seminars in the ‘Basic Nuclear Medicine’ series have been released. To access them please visit the IAEA Human Health Campus website or click on the title above. Be on the lookout for a new seminar every Monday in the Basic and Paediatric Nuclear Medicine Series.
Click Here
 

Past News Prior to 2016

Comments to USP Chapter 797-Compounding Radiopharmaceuticals-SNMMI

Read More.....

 

Notification Regarding Molybdenum-99 Supply Disruption from the NRU / Avis concernant une rupture d'approvisionnement de Molybdène-99 du réacteur NRU - November 23, 2013

In accordance with the Government of Canada protocol, Atomic Energy of Canada Limited (AECL) has advised Health Canada that the NRU has returned to service and resumed supplying molybdenum-99. 

Read More..., 


CBC News - Isoptope Supply - November 22, 2013

http://www.cbc.ca/news/health/medical-isotope-supply-interrupted-across-canada-1.2436964


Update - Mo-99 Supply - Approvisionnement en Mo-99 - Mallinckrodt - November 21, 2013

Letter to CANM Members - Situation at NRULettre aux membres de l'ACMN-NRU en panne - November 20, 2013
An update from Dr. Norman Laurin, President of the CANM regarding the NRU situation.

Notification Regarding Molybdenum-99 Supply Disruption from the NRU / Avis concernant une rupture d¹approvisionnement de Molybdène-99 du réacteur NRU - November 19, 2013 An update from Dr. Norman Laurin, President of the CANM regarding the Molybdenum-99 Supply Disruption from NRU. 
Read more....


MAA Supply - Update September 23, 2013
An update from Dr. Norman Laurin, President of the CANM regarding the supply of MAA. 
Read more...

MAA Supply - Update September 13, 2013
A letter from Dr. Norman Laurin, President of the CANM regarding the supply of MAA.
Read More....

Powered by Wild Apricot Membership Software